Cited by 668Pregnancy and preeclampsia studiesNeurological Complications and SyndromesNeonatal and fetal brain pathology

The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.

Angiogenic Factors and the Risk of Adverse Outcomes in Women With Suspected Preeclampsia

Open access

Rana, Sarosh, Powe, Camille E., Salahuddin, Saira, Verlohren, Stefan, Perschel, Frank H., Levine, Richard J., Lim, Kee-Hak, Wenger, Julia B., Thadhani, Ravi, Karumanchi, S. Ananth·2012·Circulation

DOI 10.1161/circulationaha.111.054361PMC PMC3319742

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: An imbalance in circulating angiogenic factors plays a central role in the pathogenesis of preeclampsia. METHODS AND RESULTS: We prospectively studied 616 women who were evaluated for suspected preeclampsia. We measured plasma levels of antiangiogenic soluble fms-like tyrosine kinase 1 (sFlt1) and proangiogenic placental growth factor (PlGF) at presentation and examined for an association between the sFlt1/PlGF ratio and subsequent adverse maternal and perinatal outcomes within 2 weeks. The median sFlt1/PlGF ratio at presentation was elevated in participants who experienced any adverse outcome compared with those who did not (47.0 [25th-75th percentile, 15.5-112.2] versus 10.8 [25th-75th percentile, 4.1-28.6]; P<0.0001). Among those presenting at <34 weeks (n=167), the results were more striking (226.6 [25th-75th percentile, 50.4-547.3] versus 4.5 [25th-75th percentile, 2.0-13.5]; P<0.0001), and the risk was markedly elevated when the highest sFlt1/PlGF ratio tertile was compared with the lowest (odds ratio, 47.8; 95% confidence interval, 14.6-156.6). Among participants presenting at <34 weeks, the addition of sFlt1/PlGF ratio to hypertension and proteinuria significantly improved the prediction for subsequent adverse outcomes (area under the curve, 0.93 for hypertension, proteinuria, and sFlt1/PlGF versus 0.84 for hypertension and proteinuria alone; P=0.001). Delivery occurred within 2 weeks of presentation in 86.0% of women with an sFlt1/PlGF ratio ≥85 compared with 15.8% of women with an sFlt1/PlGF ratio <85 (hazard ratio, 15.2; 95% confidence interval, 8.0-28.7). CONCLUSIONS: In women with suspected preeclampsia presenting at <34 weeks, circulating sFlt1/PlGF ratio predicts adverse outcomes occurring within 2 weeks. The accuracy of this test is substantially better than that of current approaches and may be useful in risk stratification and management. Additional studies are warranted to validate these findings.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1161/circulationaha.111.054361

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Comparing the Areas under Two or More Correlated Receiver Operating Characteristic Curves: A Nonparametric Approach
DeLong, E. R., DeLong, D. M., & Clarke-Pearson, D. L. (1988) · Biometrics · doi:10.2307/2531595 · Cited by 22,649
Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia
Maynard, S. E., Min, J.-Y., Merchan, J., Lim, K.-H., Li, J., Mondal, S., Libermann, T. A., Morgan, J. P., Sellke, F. W., Stillman, I. E., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17189 · Cited by 4,101
Self-citation
Circulating angiogenic factors and the risk of preeclampsia
Levine, R. J., Maynard, S. E., Qian, C., Lim, K.-H., England, L. J., Yu, K. F., Schisterman, E. F., Thadhani, R., Sachs, B. P., Epstein, F. H., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031884 · Cited by 3,720
Self-citation
Circulating angiogenic factors and the risk of preeclampsia*
(2004) · Obstetrics and Gynecology · doi:10.1097/00006250-200405000-00028 · Cited by 2,623
Soluble Endoglin and Other Circulating Antiangiogenic Factors in Preeclampsia
Levine, R. J., Lam, C., Qian, C., Yu, K. F., Maynard, S. E., Sachs, B. P., Sibai, B. M., Epstein, F. H., Romero, R. J., Thadhani, R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055352 · Cited by 1,823
Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor.
Kendall, R. L., & Thomas, K. A. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.22.10705 · Cited by 1,419
Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases
Eremina, V., Sood, M. M., Haigh, J. J., Nagy, A., Lajoie, G., Ferrara, N., Gerber, H. P., Kikkawa, Y., Miner, J. H., & Quaggin, S. E. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17423 · Cited by 1,308
Soluble Endoglin and Other Circulating Antiangiogenic Factors in Preeclampsia
(2006) · New England Journal of Medicine · doi:10.1056/nejmx060063 · Cited by 1,237
ACOG Practice Bulletin No. 33: Diagnosis and Management of Preeclampsia and Eclampsia
ACOG Committee on Obstetric Practice (2002) · Obstetrics and Gynecology · doi:10.1016/s0029-7844(01)01747-1 · Cited by 1,180
Secular Trends in the Rates of Preeclampsia, Eclampsia, and Gestational Hypertension, United States, 1987-2004
Wallis, A. B., Saftlas, A. F., Hsia, J., & Atrash, H. K. (2008) · American Journal of Hypertension · doi:10.1038/ajh.2008.20 · Cited by 759

Show all 39 references

Sorted by citations

Items 101–200 of 667

Angiogenic factors: potential to change clinical practice in pre‐eclampsia?
Cerdeira, A. S., Agrawal, S., Staff, A., Cw, R., & Vatish, M. (2017) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.15042 · Cited by 78
Clinical Presentation of Preeclampsia and the Diagnostic Value of Proteins and Their Methylation Products as Biomarkers in Pregnant Women with Preeclampsia and Their Newborns
Portelli, M., & Baron, B. (2018) · Journal of Pregnancy · doi:10.1155/2018/2632637 · Cited by 84
“, [61] it was suggested that the ratio of sFlt-1 to PlGF appears to be a better predictor of PE than eithermeasure alone.”
Background
Accuracy of angiogenic biomarkers at ⩽20weeks’ gestation in predicting the risk of pre-eclampsia: A WHO multicentre study
Widmer, M., Cuesta, C., Khan, K. S., Conde‐Agudelo, A., Carroli, G., Fusey, S., Karumanchi, S. A., Lapaire, O., Lumbiganon, P., Sequeira, E., et al. (2015) · Pregnancy Hypertension · doi:10.1016/j.preghy.2015.09.004 · Cited by 75
Angiogenic biomarkers for prediction of maternal and neonatal complications in suspected preeclampsia
Moore, A. G., Young, H. A., Keller, J. M., Ojo, L., Yan, J., Simas, T. A. M., & Maynard, S. E. (2012) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.3109/14767058.2012.713055 · Cited by 76
“Two studies have evaluated the utility of angiogenic biomarkers for risk stratification in women presenting to obstetrical triage with suspicion of preeclampsia [22,23].”
Background
Clinical implementation of the sFlt-1/PlGF ratio to identify preeclampsia and fetal growth restriction: A prospective cohort study
Herraı̀z, I., Simon, E. D. S., Gómez‐Arriaga, P. I., Quezada, M. S., García-Burguillo, A., López-Jiménez, E. A., & Galindo, A. (2018) · Pregnancy Hypertension · doi:10.1016/j.preghy.2018.06.017 · Cited by 72
Angiogenic factors vs Doppler surveillance in the prediction of adverse outcome among late‐pregnancy small‐for‐ gestational‐age fetuses
Lobmaier, S. M., Figueras, F., Mercade, I., Perelló, M. F., Peguero, A., Crovetto, F., Ortiz, J. U., Crispi, F., & Gratacós, E. (2013) · Ultrasound in Obstetrics and Gynecology · doi:10.1002/uog.13246 · Cited by 72
Maternal serum glycosylated fibronectin as a point-of-care biomarker for assessment of preeclampsia
Rasanen, J. P., Quinn, M. J., Laurie, A., Bean, E. S., Roberts, C. T., Nagalla, S. R., & Gravett, M. G. (2014) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2014.07.052 · Cited by 72
Update on the Pathophysiological Implications and Clinical Role of Angiogenic Factors in Pregnancy
Llurba, E., Crispi, F., & Verlohren, S. (2015) · Fetal Diagnosis and Therapy · doi:10.1159/000368605 · Cited by 76
Diagnostic accuracy of sFlt1/PlGF ratio as a marker for preeclampsia
Nikuei, P., Rajaei, M., Roozbeh, N., Mohseni, F., Poordarvishi, F., Azad, M., & Haidari, S. (2020) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-020-2744-2 · Cited by 75
Angiogenic Biomarkers in Preeclampsia
Burwick, R. M., & Rodriguez, M. H. (2024) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000005532 · Cited by 96
Predictive value of sFlt-1, PlGF, sFlt-1/PlGF ratio and PAPP-A for late-onset preeclampsia and IUGR between 32 and 37 weeks of pregnancy
Birdir, C., Droste, L., Fox, L., Frank, M., Fryze, J., Enekwe, A., Köninger, A., Kimmig, R., Schmidt, B., & Gellhaus, A. (2018) · Pregnancy Hypertension · doi:10.1016/j.preghy.2018.04.010 · Cited by 67
Circulating Angiogenic Factors and Urinary Prolactin as Predictors of Adverse Outcomes in Women With Preeclampsia
Leaños‐Miranda, A., Campos-Galicia, I., Ramírez-Valenzuela, K. L., Chinolla-Arellano, Z. L., & Isordia‐Salas, I. (2013) · Hypertension · doi:10.1161/hypertensionaha.111.00754 · Cited by 68
Placental and maternal sFlt1/PlGF expression in gestational diabetes mellitus
Nuzzo, A. M., Giuffrida, D., Moretti, L., Re, P., Grassi, G., Menato, G., & Rolfo, A. (2021) · Scientific Reports · doi:10.1038/s41598-021-81785-5 · Cited by 67
Circulating Angiogenic Factors and the Risk of Adverse Outcomes among Haitian Women with Preeclampsia
March, M. I., Geahchan, C., Wenger, J., Raghuraman, N., Berg, A. H., Haddow, H. R. M., McKeon, B. A., Narcisse, R., David, J. L., Scott, J., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0126815 · Cited by 67
“Automated assays for sFlt1 and PlGF were performed with commercially available automated assays on Elecsys platform (Roche Diagnostics) as previously described [13, 18].”
BackgroundMethod
Hypertensive Disorders of Pregnancy
Naderi, S., Tsai, S. A., & Khandelwal, A. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0648-z · Cited by 66
Competing risks model in screening for preeclampsia by serum placental growth factor and soluble fms-like tyrosine kinase-1 at 30-33 weeks’ gestation
Lai, J., Garcia-Tizon Larroca, S., Peeva, G., Poon, L. C., Wright, D., & Nicolaides, K. H. (2014) · Fetal Diagnosis and Therapy · doi:10.1159/000359968 · Cited by 63
A longitudinal study of circulating angiogenic and antiangiogenic factors and AT1-AA levels in preeclampsia
Sahay, A. S., Patil, V., Sundrani, D. P., Joshi, A. A., Wagh, G. N., Gupte, S., & Joshi, S. (2014) · Hypertension Research · doi:10.1038/hr.2014.71 · Cited by 62
Plasma Concentrations of Soluble Endoglin versus Standard Evaluation in Patients with Suspected Preeclampsia
Rana, S., Cerdeira, A. S., Wenger, J., Salahuddin, S., Lim, K.-H., Ralston, S. J., Thadhani, R., & Karumanchi, S. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048259 · Cited by 69
“The availability of automated assays for sFlt1 and PlGF, has enabled researchers to determine the clinical utility of these markers in the diagnosis and management of preeclampsia [12,13,14,15,16].”
BackgroundMethodResultInfluential
Maternal vitamin D sufficiency and reduced placental gene expression in angiogenic biomarkers related to comorbidities of pregnancy
Schulz, E. V., Cruze, L., Wei, W., Gehris, J., & Wagner, C. L. (2017) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2017.02.003 · Cited by 65
FLT1 and transcriptome-wide polyadenylation site (PAS) analysis in preeclampsia
Ashar-Patel, A., Kaymaz, Y., Rajakumar, A., Bailey, J. A., Karumanchi, S. A., & Moore, M. J. (2017) · Scientific Reports · doi:10.1038/s41598-017-11639-6 · Cited by 61
Relationship between nulliparity and preeclampsia may be explained by altered circulating soluble fms-like tyrosine kinase 1
Bdolah, Y., Elchalal, U., Natanson‐Yaron, S., Yechiam, H., Bdolah‐Abram, T., Greenfield, C., Goldman‐Wohl, D., Milwidsky, A., Rana, S., Karumanchi, S. A., et al. (2013) · Hypertension in Pregnancy · doi:10.3109/10641955.2013.858745 · Cited by 68
“sFlt1/PlGF ratios as an adverse outcome predictor (23).”
Background
Characteristics and In-Hospital Outcomes of Peripartum Cardiomyopathy Diagnosed During Delivery in the United States From the Nationwide Inpatient Sample (NIS) Database
Afana, M., Brinjikji, W., Kao, D. P., Jackson, E. A., Maddox, T. M., Childers, D. M., Eagle, K. A., & Davis, M. B. (2016) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2016.02.008 · Cited by 60
Low Soluble Fms-Like Tyrosine Kinase-1, Endoglin, and Endothelin-1 Levels in Women With Confirmed or Suspected Preeclampsia Using Proton Pump Inhibitors
Saleh, L., Samantar, R., Garrelds, I. M., van den Meiracker, A. H., Visser, W. E., & Danser, A. H. J. (2017) · Hypertension · doi:10.1161/hypertensionaha.117.09741 · Cited by 60
Usefulness of the sFlt-1/PlGF (Soluble fms-Like Tyrosine Kinase-1/Placental Growth Factor) Ratio in Diagnosis or Misdiagnosis in Women With Clinical Diagnosis of Preeclampsia
Leaños‐Miranda, A., Nolasco-Leaños, A. G., Carrillo-Juárez, R. I., Molina-Pérez, C. J., Sillas-Pardo, L. J., Jiménez-Trejo, L. M., Isordia‐Salas, I., & Ramírez-Valenzuela, K. L. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.15552 · Cited by 59
“Lastly, according to our cutoffs studied for the sFlt/PlGF ratio, it was found that the rates for ruling out preeclampsia within 7 days, subsequent development of preeclampsia, diagnosis of preeclampsia within 7 and 28 days, and delivery or occurrence of adverse outcomes within 2 weeks were similar to those yielded by…”
Result
Chemical optimization of siRNA for safe and efficient silencing of placental sFLT1
Davis, S. M., Hariharan, V. N., Lo, A. S., Turanov, A. A., Echeverria, D., Sousa, J., McHugh, N., Biscans, A., Alterman, J. F., Karumanchi, S. A., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.06.009 · Cited by 61
Predictive value of the sFlt‑1/PlGF ratio in women with suspected preeclampsia: An update (Review)
Velegrakis, A., Kouvidi, E., Fragkiadaki, P., & Sifakis, S. (2023) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2023.5292 · Cited by 85
“Rana et al (55) observed that women with a non‑angiogenic form of PE (sFlt‑1/PlGF ratio 85) had very low risk of adverse outcomes.”
Uterine artery Doppler and sFlt ‐1/ PlGF ratio: prognostic value in early‐onset pre‐eclampsia
Gómez‐Arriaga, P. I., Herraı̀z, I., López-Jiménez, E. A., Escribano, D., Denk, B., & Galindo, A. (2013) · Ultrasound in Obstetrics and Gynecology · doi:10.1002/uog.13224 · Cited by 59
Diagnosis and Treatment of Hypertensive Pregnancy Disorders. Guideline of DGGG (S1-Level, AWMF Registry No. 015/018, December 2013)
Stepan, H., Kuse-Föhl, S., Klockenbusch, W., Rath, W. H., Schauf, B., Walther, T., & Schlembach, D. (2015) · Geburtshilfe und Frauenheilkunde · doi:10.1055/s-0035-1557924 · Cited by 60
Relationship between hypoxia and downstream pathogenic pathways in preeclampsia
Korkes, H. A., Oliveira, L. G., Sass, N., Salahuddin, S., Karumanchi, S. A., & Rajakumar, A. (2017) · Hypertension in Pregnancy · doi:10.1080/10641955.2016.1259627 · Cited by 61
Micro- and Nano-vesicles from First Trimester Human Placentae Carry Flt-1 and Levels Are Increased in Severe Preeclampsia
Tong, M., Chen, Q., James, J. L., STONE, P. R., & Chamley, L. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00174 · Cited by 57
Diagnostic utility of serial circulating placental growth factor levels and uterine artery Doppler waveforms in diagnosing underlying placental diseases in pregnancies at high risk of placental dysfunction
Agrawal, S., Parks, W. T., Zeng, H. D., Ravichandran, A., Ashwal‏, E., Windrim, R. C., Hobson, S. R., Melamed, N., & Kingdom, J. C. (2022) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2022.05.043 · Cited by 57
Serum soluble fms‐like tyrosine kinase‐1 in the three trimesters of pregnancy: effects of maternal characteristics and medical history
Tsiakkas, A., Duvdevani, N., Wright, A., Wright, D. E., & Nicolaides, K. H. (2015) · Ultrasound in Obstetrics and Gynecology · doi:10.1002/uog.14817 · Cited by 56
The association of falling insulin requirements with maternal biomarkers and placental dysfunction: a prospective study of women with preexisting diabetes in pregnancy
Padmanabhan, S., Lee, V. W., Mclean, M., Athayde, N., Lanzarone, V., Khoshnow, Q., Peek, M. J., & Cheung, N. W. (2017) · Diabetes Care · doi:10.2337/dc17-0391 · Cited by 55
A comparison of the diagnostic utility of the sFlt-1/PlGF ratio versus PlGF alone for the detection of preeclampsia/HELLP syndrome
Stepan, H., Hund, M., Gencay, M., Denk, B., Dinkel, C., Kaminski, W. E., Wieloch, P., Semus, B., Meloth, T., Dröge, L.-A., et al. (2016) · Hypertension in Pregnancy · doi:10.3109/10641955.2016.1141214 · Cited by 55
“In women with suspected preeclampsia presenting at <34 weeks, the circulating sFlt-1/ PlGF ratio predicted adverse outcomes (including iatrogenic delivery, small for gestational age birth weight, fetal/neonatal death) occurring within 2 weeks (20).”
BackgroundMethodInfluential
Trophoblast-Targeted Nanomedicine Modulates Placental sFLT1 for Preeclampsia Treatment
Li, L., Yang, H., Chen, P., Xin, T., Zhou, Q., Wei, D., Zhang, Y., & Wang, S. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00064 · Cited by 54
The relationship of angiogenic factors to maternal and neonatal manifestations of early‐onset and late‐onset preeclampsia
Pinheiro, C. C., Rayol, P., Gozzani, L., dos Reis, L. M., Zampieri, G., Dias, C. B., & Woronik, V. (2014) · Prenatal Diagnosis · doi:10.1002/pd.4432 · Cited by 56
“Other authors have obtained similar results, showing that the sFlt-1/PlGF ratio is associated with adverse outcomes in patients with early-onset preeclampsia.(10)”
BackgroundResultInfluential
Angiogenic Markers Predict Pregnancy Complications and Prolongation in Preeclampsia
Saleh, L., Vergouwe, Y., van den Meiracker, A. H., Verdonk, K., Russcher, H., Bremer, H. A., Versendaal, H., Steegers, E. A. P., Danser, A. H. J., & Visser, W. E. (2017) · Hypertension · doi:10.1161/hypertensionaha.117.09913 · Cited by 54
The association of circulating angiogenic factors and HbA1c with the risk of preeclampsia in women with preexisting diabetes
Cohen, A., Wenger, J., James-Todd, T. M., Lamparello, B. M., Halprin, E., Serdy, S., Fan, S., Horowitz, G. L., Lim, K.-H., Rana, S., et al. (2013) · Hypertension in Pregnancy · doi:10.3109/10641955.2013.837175 · Cited by 56
“The ratio takes into account both the increase in sFlt1 and the decrease in PlGF in women who develop PE and appears to be a more reliable index for the prediction of PE than either protein alone (16,23).”
Background
TLR9 (Toll-Like Receptor 9) Agonist Suppresses Angiogenesis by Differentially Regulating VEGFA (Vascular Endothelial Growth Factor A) and sFLT1 (Soluble Vascular Endothelial Growth Factor Receptor 1) in Preeclampsia
He, B., Yang, X., Li, Y., Huang, D., Xu, X., Yang, W., Dai, Y., Zhang, H., Chen, Z., & Cheng, W. (2018) · Hypertension · doi:10.1161/hypertensionaha.117.10510 · Cited by 54
Is It Possible to Differentiate Chronic Kidney Disease and Preeclampsia by means of New and Old Biomarkers? A Prospective Study
Rolfo, A., Attini, R., Tavassoli, E., Neve, F. V., Nigra, M., Cicilano, M., Nuzzo, A. M., Giuffrida, D., Biolcati, M., Nichelatti, M., et al. (2015) · Disease Markers · doi:10.1155/2015/127083 · Cited by 53
Circulating angiogenic factors are related to the severity of gestational hypertension and preeclampsia, and their adverse outcomes
Leaños‐Miranda, A., Méndez-Aguilar, F., Ramírez-Valenzuela, K. L., Serrano-Rodríguez, M., Berumen-Lechuga, G., Molina-Pérez, C. J., Isordia‐Salas, I., & Campos-Galicia, I. (2017) · Medicine · doi:10.1097/md.0000000000006005 · Cited by 51
“Keywords: adverse perinatal and maternal outcomes, angiogenic factors, hypertensive disorders of pregnancy”
Background
Research Recommendations From the National Institutes of Health Workshop on Predicting, Preventing, and Treating Preeclampsia
Maric‐Bilkan, C., Abrahams, V. M., Arteaga, S. S., Bourjeily, G. R., Conrad, K. P., Catov, J. M., Costantine, M. M., Cox, B., Garovic, V. D., George, E. M., et al. (2019) · Hypertension · doi:10.1161/hypertensionaha.118.11644 · Cited by 57
Glomerular diseases in pregnancy: pragmatic recommendations for clinical management
Fakhouri, F., Schwotzer, N., Cabiddu, G., Barratt, J., Legardeur, H., Garovic, V. D., Orozco-Guillén, A., Wetzels, J. F. M., Daugas, É., Moroni, G. L., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.10.029 · Cited by 52
Exercise Training Attenuates Placental Ischemia-Induced Hypertension and Angiogenic Imbalance in the Rat
Gilbert, J. S., Banek, C. T., Bauer, A. J., Gingery, A., & Needham, K. W. (2012) · Hypertension · doi:10.1161/hypertensionaha.112.202275 · Cited by 52
Longitudinal changes in maternal serum placental growth factor and soluble fms‐like tyrosine kinase‐1 in women at increased risk of pre‐eclampsia
Khalil, A. A., Maíz, N., Garcia‐Mandujano, R., Penco, J. M. P., & Nicolaides, K. H. (2015) · Ultrasound in Obstetrics and Gynecology · doi:10.1002/uog.15750 · Cited by 52
Angiogenic Marker Prognostic Models in Pregnant Women With Hypertension
Perry, H., Binder, J., Kalafat, E., Jones, S., Thilaganathan, B., & Khalil, A. A. (2020) · Hypertension · doi:10.1161/hypertensionaha.119.13997 · Cited by 52
“Their findings have suggested that pregnancies with preeclampsia and angiogenic imbalance (sFlt-1/PLGF ratio >85) had worse outcomes and a shorter diagnosis to delivery interval.(27) Rana et al have also demonstrated that different levels of sFlt-1/PlGF confer to varying risk odds.”
Background
Cost and resource implications with serum angiogenic factor estimation in the triage of pre‐eclampsia
Schnettler, W. T., Dukhovny, D., Wenger, J., Salahuddin, S., Ralston, S. J., & Rana, S. (2013) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.12259 · Cited by 51
The role of angiogenic factors in the management of preeclampsia
Flint, E. J., Cerdeira, A. S., Redman, C. W. G., & Vatish, M. (2019) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1111/aogs.13540 · Cited by 52
A Review of Research Progress of Pregnancy with Twins with Preeclampsia
Wang, Y., Wu, N., & Shen, H. (2021) · Risk Management and Healthcare Policy · doi:10.2147/rmhp.s304040 · Cited by 56
“The severity of maternal antiangiogenesis in preeclampsia patients in the third trimester of pregnancy may be more accurate than elevated blood pressure in predicting the occurrence of preeclampsia complications.(80,81) In pregnant women with Preeclampsia within 34 weeks, the sFlt-1/PlGF ratio was 85, which could pred…”
Background
KRYPTOR-automated angiogenic factor assays and risk of preeclampsia-related adverse outcomes
Salahuddin, S., Wenger, J., Zhang, D., Thadhani, R., Karumanchi, S. A., & Rana, S. (2016) · Hypertension in Pregnancy · doi:10.3109/10641955.2016.1148162 · Cited by 49
“We led a large prospective study that demonstrated the plasma sFlt1/ PlGF ratio predicts adverse maternal and perinatal outcomes (occurring within 2 weeks) in the preterm setting (9).”
BackgroundMethodInfluential
Total Versus Free Placental Growth Factor Levels in the Pathogenesis of Preeclampsia
Lecarpentier, É., Zsengellér, Z. K., Salahuddin, S., Covarrubias, A. E., Lo, A. S., Haddad, B., Thadhani, R., & Karumanchi, S. A. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.15338 · Cited by 49
Screening for pre‐eclampsia using sFlt‐1/PlGF ratio cut‐off of 38 at 30–37 weeks' gestation
Dragan, I., Georgiou, T., Prodan, N., Akolekar, R., & Nicolaides, K. H. (2016) · Ultrasound in Obstetrics and Gynecology · doi:10.1002/uog.17301 · Cited by 48
Angiogenic Factor Estimation as a Warning Sign of Preeclampsia-Related Peripartum Morbidity Among Hospitalized Patients
Perdigao, J. L., Chinthala, S., Mueller, A., Minhas, R., Ramadan, H., Nasim, R., Naseem, H., Young, D. R., Shahul, S., Chan, S. L., et al. (2019) · Hypertension · doi:10.1161/hypertensionaha.118.12205 · Cited by 48
“This limits the generalizability of our data; however, prior studies of angiogenic factors have been done in populations comprised primarily of white women and have yielded similar results.(9,10) Although blood samples were collected prospectively, much of the chart data was collected retrospectively and, therefore, c…”
Result
Integrating multiple ‘omics’ analyses identifies serological protein biomarkers for preeclampsia
Liu, L. Y., Yang, T., Ji, J., Wen, Q., Morgan, A. A., Jin, B., Chen, G., Lyell, D. J., Stevenson, D. K., Ling, X. B., et al. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-236 · Cited by 48
Spiral Artery Remodeling in Preeclampsia Revisited
Burke, S. D., & Karumanchi, S. A. (2013) · Hypertension · doi:10.1161/hypertensionaha.113.02049 · Cited by 47
“In light of this, the authors might have considered inclusion of plasma biomarkers, such as angiogenic factors, which more closely correlate to adverse maternal and fetal outcomes than clinical diagnostic criteria that rely on nonspecific signs and symptoms.(14) Finally, more pathological features should have been exa…”
Background
Full-length human placental sFlt-1-e15a isoform induces distinct maternal phenotypes of preeclampsia in mice
Szalai, G., Romero, R., Chaiworapongsa, T., Xu, Y., Wang, B., Ahn, H., Xu, Z., Chiang, P. J., Sundell, B., Wang, R., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0119547 · Cited by 46
Diagnosis of preeclampsia with soluble Fms–like tyrosine kinase 1/placental growth factor ratio: an inter–assay comparison
Andersen, L. B., Frederiksen‐Møller, B., Havelund, K. W., Dechend, R., Jørgensen, J. S., Jensen, B. L., Nielsen, J., Lykkedegn, S., Barington, T., & Christesen, H. T. (2014) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2014.11.008 · Cited by 46
“This confirms observations from previous studies.(27,28) Only 21/39 (54%) of cases with preeclampsia were non–obese.”
Result
New advances in prediction and surveillance of preeclampsia: role of machine learning approaches and remote monitoring
Hackelöer, M., Schmidt, L., & Verlohren, S. (2022) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-022-06864-y · Cited by 50
“1 3 [31] but also for preeclampsia-associated adverse outcomes [21, 22].”
Background
Preeclampsia history and postpartum risk of cerebrovascular disease and cognitive impairment: Potential mechanisms
Beckett, A. G., McFadden, M. D., & Warrington, J. P. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1141002 · Cited by 48
“The anti-angiogenic protein, Soluble fms-like tyrosine kinase -1 (sFlt-1), has been shown to be elevated in pregnant women (Maynard et al., 2003; Rana et al., 2012).”
Background
Ouabain inhibits placental sFlt1 production by repressing HSP27‐dependent HIF‐1α pathway
Rana, S., Rajakumar, A., Geahchan, C., Salahuddin, S., Cerdeira, A. S., Burke, S. D., George, E. M., Granger, J. P., & Karumanchi, S. A. (2014) · The FASEB Journal · doi:10.1096/fj.14-252684 · Cited by 46
“Circulating sFlt1 levels are increased prior to onset of preeclampsia, are altered in most women with severe preeclampsia, and correlate with adverse maternal and neonatal outcomes related to preeclampsia (6, 7).”
Background
Preeclampsia at term can be classified into 2 clusters with different clinical characteristics and outcomes based on angiogenic biomarkers in maternal blood
Chaiworapongsa, T., Romero, R. J., Gotsch, F., Suksai, M., Gallo, D. M., Jung, E., Krieger, A., Chaemsaithong, P., Erez, O., & Tarca, A. L. (2022) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2022.11.001 · Cited by 46
Prediction and prevention of hypertensive disorders of pregnancy
Ohkuchi, A., Hirashima, C., Takahashi, K., Suzuki, H., & Matsubara, S. (2016) · Hypertension Research · doi:10.1038/hr.2016.107 · Cited by 44
Validation of Fetal Medicine Foundation algorithm for prediction of pre-eclampsia in the first trimester in an unselected Brazilian population
Lobo, G. A. R., NOWAK, P. M., Panigassi, A. P., Lima, A. I. F., Júnior, E. A., Nardozza, L. M. M., & Pares, D. B. S. (2017) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767058.2017.1378332 · Cited by 46
“[34] included on their algorithm the s-FLT, an anti-angiogenic factor that has been extensively studied in the diagnosis [35,36] and prognosis [37] of PE, but with an uncertain whole and conflicting results regarding prediction.”
Background
Procyanidin B2 ameliorates endothelial dysfunction and impaired angiogenesis via the Nrf2/PPARγ/sFlt-1 axis in preeclampsia
Liu, L., Wang, R., Xu, R., Chu, Y., & Gu, W. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106127 · Cited by 46
Earlier Detection Can Help Avoid Many Serious Complications of Peripartum Cardiomyopathy
Fett, J. D. (2013) · Future Cardiology · doi:10.2217/fca.13.63 · Cited by 44
“Angiogenic imbalance A recently identified enzyme in the tyrosine kinase family, sFLT1, appears to be antiangiogenic, cardiotoxic and particularly elevated in both PPCM and pre-eclampsia [38,39].”
Peripartum cardiomyopathy: A puzzle closer to solution
Fett, J. D. (2014) · World Journal of Cardiology · doi:10.4330/wjc.v6.i3.87 · Cited by 41
Placental growth factor (alone or in combination with soluble fms-like tyrosine kinase 1) as an aid to the assessment of women with suspected pre-eclampsia: systematic review and economic analysis
Frampton, G. K., Jones, J., Rose, M., & Payne, L. (2016) · Health Technology Assessment · doi:10.3310/hta20870 · Cited by 46
“The sFlt-1 to PlGF ratio threshold value adopted in the study was ≥ 85 (referenced to Rana et al.(102)).”
Method
Placental expression of sFlt-1 and PlGF in early preeclampsia vs. early IUGR vs. age-matched healthy pregnancies
Hoeller, A., Ehrlich, L. C., Golić, M., Herse, F., Perschel, F. H., Siwetz, M., Henrich, W., Dechend, R., Huppertz, B., & Verlohren, S. (2017) · Hypertension in Pregnancy · doi:10.1080/10641955.2016.1273363 · Cited by 43
Soluble fms‐like tyrosine kinase‐1 and placental growth factor kinetics during and after pregnancy in women with suspected or confirmed pre‐eclampsia
Saleh, L., van den Meiracker, A. H., Geensen, R., Kaya, A., van Lennep, J. E. R., Duvekot, J. J., Verdonk, K., Steegers, E., Russcher, H., Danser, A. H. J., et al. (2017) · Ultrasound in Obstetrics and Gynecology · doi:10.1002/uog.17547 · Cited by 44
“002 Gestational hypertension 4 (9) — 4 (25) 0.”
Altered Hemodynamics and Hyperuricemia Accompany an Elevated sFlt-1/PlGF Ratio Before the Onset of Early Severe Preeclampsia
Doherty, A., Carvalho, J. C. A., Drewlo, S., EL-Khuffash, A. F., Downey, K., Dodds, M., & Kingdom, J. C. (2014) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/s1701-2163(15)30511-9 · Cited by 42
sFlt ‐1/ PlGF ratio and timing of delivery in early‐onset fetal growth restriction with antegrade umbilical artery flow
Quezada, M. S., Rodríguez‐Calvo, J., Villalaín, C., Gómez‐Arriaga, P. I., Galindo, A., & Herraı̀z, I. (2019) · Ultrasound in Obstetrics and Gynecology · doi:10.1002/uog.21949 · Cited by 42
The Prognostic Value of Angiogenic Markers in Twin Pregnancies to Predict Delivery Due to Maternal Complications of Preeclampsia
Binder, J., Palmrich, P., Pateisky, P., Kalafat, E., Kuessel, L., Zeisler, H., Munkhbaatar, M., Windsperger, K., Thilaganathan, B., & Khalil, A. A. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.14957 · Cited by 40
“Clinical factors such as proteinuria or uric acid levels are poor predictors of adverse outcomes and markers that are more sensitive and specific would be beneficial for selecting women who would benefit from early delivery versus women who should be expectantly managed.(8,9) SFlt-1 (soluble fms-like tyrosine kinase-1…”
Background
Blood Pressure and Angiogenic Markers in Pregnancy
Birukov, A., Herse, F., Nielsen, J. H., Kyhl, H. B., Golić, M., Kräker, K., Haase, N., Busjahn, A., Bruun, S., Jensen, B. L., et al. (2020) · Hypertension · doi:10.1161/hypertensionaha.119.13966 · Cited by 41
“Circulating angiogenic markers sFlt-1 (soluble fms-like tyrosine kinase-1) and PlGF (placental growth factor) are released from the placenta and endothelium, and their imbalance plays a pivotal role in the pathogenesis of preeclampsia.(17,18) Gishti et al(19) found that microvascular resistance in childhood, expressed…”
Background
Placental lesions of vascular insufficiency are associated with anti-angiogenic state in women with preeclampsia
Baltajian, K., Hecht, J. L., Wenger, J., Salahuddin, S., Verlohren, S., Perschel, F. H., Zsengellér, Z. K., Thadhani, R., Karumanchi, S. A., & Rana, S. (2014) · Hypertension in Pregnancy · doi:10.3109/10641955.2014.926914 · Cited by 41
“Moreover, in patients with suspected preeclampsia, alterations in circulating angiogenic factors correlate with adverse outcomes related to placental insufficiency such as severe fetal growth restriction and fetal death (11,13,28,29).”
BackgroundMethodInfluential
Smooth Muscle Mineralocorticoid Receptor Promotes Hypertension After Preeclampsia
Biwer, L. A., Lu, Q. R., Ibarrola, J., Stepanian, A., Man, J. J., Carvajal, B. V., Camarda, N. D., Zsengellér, Z. K., Skurnik, G., Seely, E. W., et al. (2023) · Circulation Research · doi:10.1161/circresaha.122.321228 · Cited by 40
Low-Molecular Weight Heparin Increases Circulating sFlt-1 Levels and Enhances Urinary Elimination
Hagmann, H., Boßung, V., Belaidi, A. A., Fridman, A., Karumanchi, S. A., Thadhani, R., Schermer, B., Mallmann, P. K., Schwarz, G., Benzing, T. R., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085258 · Cited by 39
“There is a large body of evidence that these biomarkers may help not only in the early diagnosis of preeclampsia, but also help with prediction of adverse maternal and fetal outcomes [4,5,9,34–39].”
Background
Real-world data on the clinical use of angiogenic factors in pregnancies with placental dysfunction
Dathan‐Stumpf, A., Czarnowsky, V., Hein, V., Andraczek, T., & Stepan, H. (2021) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2020.10.028 · Cited by 40
“In some international studies, immediate delivery within 48 hours is recommended in cases where a severely elevated sFlt-1etoePlGF ratio is measured (655 in early-onset PE; >201 in late-onset PE) to prevent an adverse maternal outcome.(27,28) However, it is clear that the sFlt-1etoePlGF ratio is not only a diagnostic…”
Background
Cardiovascular Diseases
Maier, C. L., Burek, C. L., Rose, N. R., & Ansari, A. A. (2016) · ASM Press eBooks · doi:10.1128/9781555818722.ch102 · Cited by 42
Perspectives on the Use of Placental Growth Factor (PlGF) in the Prediction and Diagnosis of Pre-Eclampsia: Recent Insights and Future Steps
Creswell, L., O’Gorman, N., Palmer, K. R., Costa, F. D. S., & Rolnik, D. L. (2023) · International Journal of Women s Health · doi:10.2147/ijwh.s368454 · Cited by 68
Adrenergic Receptors
Ciccarelli, M., Sorriento, D., Coscioni, E., Iaccarino, G., & Santulli, G. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803111-7.00011-7 · Cited by 40
Anti-angiogenesis and Preeclampsia in 2016
Schrey-Petersen, S., & Stepan, H. (2017) · Current Hypertension Reports · doi:10.1007/s11906-017-0706-5 · Cited by 40
The predictive value of the sFlt-1/PlGF ratio on short-term absence of preeclampsia and maternal and fetal or neonatal complications in twin pregnancies
Saleh, L., Tahitu, S. I. M., Danser, A. H. J., van den Meiracker, A. H., & Visser, W. E. (2018) · Pregnancy Hypertension · doi:10.1016/j.preghy.2018.03.014 · Cited by 39
Differential Diagnosis of Preeclampsia
Verdonk, K., Visser, W. E., Russcher, H., Danser, A. H. J., Steegers, E. A. P., & van den Meiracker, A. H. (2012) · Hypertension · doi:10.1161/hypertensionaha.112.201459 · Cited by 38
Maternal Serum Angiogenic Factor sFlt-1 to PlGF Ratio in Preeclampsia: A Useful Marker for Differential Diagnosis and Prognosis Evaluation in Chinese Women
Lou, W.-Z., Jiang, F., Hu, J., Chen, X., Song, Y., Zhou, X., Liu, J., Bian, X.-M., & Gao, J. (2019) · Disease Markers · doi:10.1155/2019/6270187 · Cited by 38
Combination Antiretroviral Therapy and Hypertensive Disorders of Pregnancy
Saums, M. K., King, C. C., Adams, J. C., Sheth, A. N., Badell, M. L., Young, M. R., Yee, L. M., CHADWICK, E. G., Jamieson, D. J., & Haddad, L. B. (2019) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000003584 · Cited by 38
“Tobacco 54 (20) 23 (25) 25 (17) 6 (21) .”
Placental growth factor in suspected preterm pre‐eclampsia: a review of the evidence and practicalities of implementation
Hurrell, A., Beardmore‐Gray, A., Duhig, K. E., Webster, L., Chappell, L. C., & Shennan, A. H. (2020) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.16425 · Cited by 39
Adverse maternal and fetal outcomes and deaths related to preeclampsia and eclampsia in Haiti
Raghuraman, N., March, M. I., Hacker, M. R., Modest, A. M., Wenger, J., Narcisse, R., David, J. L., Scott, J. A., & Rana, S. (2014) · Pregnancy Hypertension · doi:10.1016/j.preghy.2014.09.002 · Cited by 39
“This study is described in detail elsewhere [10].”
BackgroundMethodInfluential
Placenta at single-cell resolution in early and late preeclampsia: insights and clinical implications
Solt, I., Cohen, S. M., Admati, I., Beharier, O., Dominsky, O., & Yagel, S. (2025) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2025.01.041 · Cited by 41
Competing Risks Model in Screening for Preeclampsia by Biophysical and Biochemical Markers at 30-33 Weeks' Gestation
Larroca, S. G., Tayyar, A., Poon, L. C., Wright, D. E., & Nicolaides, K. H. (2014) · Fetal Diagnosis and Therapy · doi:10.1159/000362518 · Cited by 37
The association between angiogenic markers and fetal sex: Implications for preeclampsia research
Andersen, L. B., Jørgensen, J. S., Herse, F., Andersen, M., Christesen, H. T., & Dechend, R. (2016) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2016.05.005 · Cited by 37
Real life outpatient biomarker use in management of hypertensive pregnancies in third trimester in a low resource SeTting: ROBUST study
Soundararajan, R., Suresh, S. C., Mueller, A., Heimberger, S., Avula, S., Sathyanarayana, C., Mahesh, S., Madhuprakash, S., & Rana, S. (2020) · Pregnancy Hypertension · doi:10.1016/j.preghy.2020.11.010 · Cited by 36
Prevalence, maternal characteristics, and birth outcomes of preeclampsia: A cross-sectional study in a single tertiary healthcare center in greater Kuala Lumpur Malaysia
Sutan, R., Aminuddin, N. A., & Mahdy, Z. A. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.973271 · Cited by 39
Uterine artery Doppler and sFlt ‐1/ PlGF ratio: usefulness in diagnosis of pre‐eclampsia
Gómez‐Arriaga, P. I., Herraı̀z, I., López-Jiménez, E. A., Gómez‐Montes, E., Denk, B., & Galindo, A. (2013) · Ultrasound in Obstetrics and Gynecology · doi:10.1002/uog.12400 · Cited by 36
Angiogenic factors in preeclampsia
Goel, A., & Rana, S. (2013) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e328365ad98 · Cited by 37
Proposed clinical management of pregnancies after combined screening for pre-eclampsia at 30-34 weeks' gestation
Wright, D., Dragan, I., Syngelaki, A., Akolekar, R., & Nicolaides, K. H. (2016) · Ultrasound in Obstetrics and Gynecology · doi:10.1002/uog.17309 · Cited by 36
N-terminal pro B-type natriuretic peptide and angiogenic biomarkers in the prognosis of adverse outcomes in women with suspected preeclampsia
Álvarez-Fernández, I., García, B. P., Rodríguez, V., Ruano, Y., Escudero, A. I., & Álvarez, F. V. (2016) · Clinica Chimica Acta · doi:10.1016/j.cca.2016.10.033 · Cited by 36
“A strong correlation was found between NT-proBNP levels and time to delivery since clinical presentation especially in women before 34 weeks of gestation, a pattern previously reported for uric acid [37] and sFlt-1/PlGF ratio [11,13,38,39].”
Pre-eclampsia causes adverse maternal outcomes across the gestational spectrum
Pettit, F. M., Mangos, G., Davis, G. K., Henry, A., & Brown, M. A. (2015) · Pregnancy Hypertension · doi:10.1016/j.preghy.2015.02.002 · Cited by 36
“It is likely that predictive tests such the sFlt1:PlGF ratio may be helpful in identifying those women with EOP who will deliver early and hence have worse foetal outcomes [33].”
Background
Biomarkers in Peripartum Cardiomyopathy—What We Know and What Is Still to Be Found
Kryczka, K., Demkow, M., & Dzielińska, Z. (2024) · Biomolecules · doi:10.3390/biom14010103 · Cited by 44
“However, in clinical settings, a cut-off value of 85 ng/mL is considered to foresee preeclampsia [55,56].”
Background
Modeling risk for severe adverse outcomes using angiogenic factor measurements in women with suspected preterm preeclampsia
Palomaki, G. E., Haddow, J. E., Haddow, H. R. M., Salahuddin, S., Geahchan, C., Cerdeira, A. S., Verlohren, S., Perschel, F. H., Horowitz, G. L., Thadhani, R., et al. (2015) · Prenatal Diagnosis · doi:10.1002/pd.4554 · Cited by 35
“We reported that over 95% of selected adverse outcomes in women with suspected preterm PE were associated with significant abnormalities in angiogenic factors.(23) Rates of adverse outcomes among women with sFlt1/PlGF ratios <85 were low and generally unrelated to PE,(25) and others have reported similar findings.”
MethodResultInfluential
Imaging of Cerebrovascular Disease in Pregnancy and the Puerperium
Hacein‐Bey, L., Varelas, P. N., Ulmer, J. L., Mark, L. P., Raghavan, K., & Provenzale, J. M. (2015) · American Journal of Roentgenology · doi:10.2214/ajr.15.15059 · Cited by 35
“Furthermore, increasing molecular and clinical evidence suggests that postpartum angiopathy, reversible cerebral vasoconstriction syndrome (RCVS), posterior reversible encephalopathy syndrome (PRES), and possibly some expressions of thrombophilia all may represent a constellation of related conditions at the extreme,…”
Background

Authors: Rana, S., Powe, C. E., Salahuddin, S., Verlohren, S., Perschel, F. H., Levine, R. J., Lim, K.-H., Wenger, J. B., Thadhani, R., & Karumanchi, S. A.
Affiliations: National Institutes of Health (US)
ORCID: Rana, Sarosh
Powe, Camille E.
Verlohren, Stefan
Perschel, Frank H.
Wenger, Julia B.
Thadhani, Ravi
Karumanchi, S. Ananth
Venue: Circulation
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2012-02-21
Volume: 125
Issue: 7
Pages: 911-919
ISSN: 0009-7322 (ISSN-L)
1524-4539
DOI: 10.1161/circulationaha.111.054361
PMC: PMC3319742
OpenAlex: W2134502189
Cited by: 668
References: 39
Citations by year: 2026: 30 · 2025: 51 · 2024: 40 · 2023: 46 · 2022: 50 · 2021: 52 · 2020: 49 · 2019: 48 · 2018: 49 · 2017: 48 · 2016: 49 · 2015: 42 · 2014: 49 · 2013: 41 · 2012: 20
FWCI: 58.66
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Circulation (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: Howard Hughes Medical Institute
Topics: Health Sciences › Medicine › Obstetrics and Gynecology › Pregnancy and preeclampsia studies
Health Sciences › Medicine › Clinical Neurology › Neurological Complications and Syndromes
Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Neonatal and fetal brain pathology
Keywords: preeclampsia, angiogenic factors, soluble fms-like tyrosine kinase-1, placental growth factor, sFlt-1/PlGF ratio, adverse maternal outcomes, perinatal outcomes, early-onset preeclampsia, proteinuria, hypertension, adverse outcome prediction, preterm birth, placental insufficiency, endothelial dysfunction, maternal morbidity
MeSH terms: Placenta Growth Factor, Adult, Female, Humans, Pre-Eclampsia, Pregnancy, Pregnancy Proteins, Prospective Studies, Risk, ROC Curve, Systole, Logistic Models, Vascular Endothelial Growth Factor Receptor-1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Angiogenic Factors and the Risk of Adverse Outcomes in Women With Suspected Preeclampsia

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks